Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Status:
Terminated

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.

Phase 2

Repros Therapeutics Inc.

Leuprolide